The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Comparison of the Effectiveness and Tolerability of Intravenous or Oral Glucocorticoids Associated with Orbital Radiotherapy in the Management of Severe Graves' Ophthalmopathy: Results of a Prospective, Single-Blind, Randomized Study
Abstract
Eighty-two consecutive patients with moderate-to-severe and active Graves' ophthalmopathy were randomly treated with orbital radiotherapy combined with either oral (prednisone; starting dose, 100 mg/d; withdrawal after 5 months) or iv (methylprednisolone; 15 mg/kg for four cycles and then 7.5 mg/kg for four cycles; each cycle consisted of two infusions on alternate days at 2-wk intervals) glucocorticoids. The two groups did not differ for age, gender, duration of hyperthyroidism and ophthalmopathy, prevalence of smokers, thyroid volume, and pretreatment ocular conditions. Both groups of patients received radioiodine therapy shortly before treatment for Graves' ophthalmopathy. Follow-up lasted for 12 months. A significant reduction in proptosis (from 23.2 +/- 3.0 to 21.6 +/- 1.2 mm in the iv glucocorticoid group, P < 0.0001; and from 23 +/- 1.8 to 21.7 +/- 1.8 mm in oral glucocorticoid group, P < 0.0001) and in lid width (from 13.3 +/- 2.5 to 11.8 +/- 2.2 mm, and from 13.6 +/- 2.0 to 11.5 +/- 1.9 mm, respectively; P < 0.001 in both cases) occurred, with no difference between the two groups. Diplopia significantly improved in both groups: it disappeared in 13 of 27 (48.1%) iv glucocorticoid patients (P < 0.005) and in 12 of 33 (36.4%) oral glucocorticoid patients (P < 0.03). The degree of amelioration of diplopia did not significantly differ between the two groups (P = 0.82). Optic neuropathy improved in 11 of 14 iv glucocorticoid (P < 0.01) and only in 3 of 9 oral glucocorticoid (P = 0.57) patients, with no significant difference in these outcomes. The Clinical Activity Score decreased from 4.5 +/- 1.2 to 1.7 +/- 1.0 (P < 0.0001) in the iv glucocorticoid group and from 4.2 +/- 1.1 to 2.2 +/- 1.2 (P < 0.0001) in the oral glucocorticoid group; final Clinical Activity Score was significantly lower in iv glucocorticoid than in oral glucocorticoid patients (P < 0.01). By self-assessment evaluation, 35 (85.3%) iv glucocorticoid and 30 (73.2%) oral glucocorticoid patients reported an improvement of ocular conditions (P = 0.27). Overall, both treatments produced favorable effects in most patients, but responders in the iv glucocorticoid group (36 of 41, 87.8%) were more than in the oral glucocorticoid group (26 of 41, 63.4%) (P < 0.02). Moreover, iv glucocorticoid treatment was better tolerated than oral glucocorticoid treatment. Side effects occurred in 23 (56.1%) iv glucocorticoid and 35 (85.4%) oral glucocorticoid patients (P < 0.01); in particular, cushingoid features developed in 5 of the former and 35 of the latter patients. One iv glucocorticoid patient had severe hepatitis of undetermined origin at the end of glucocorticoid treatment, followed by spontaneous recovery. In conclusion, high-dose iv glucocorticoid and oral glucocorticoid (associated with orbital radiotherapy) are effective in the management of severe Graves' ophthalmopathy, but the iv route seems to be more effective and better tolerated than the oral route and associated with a lower rate of side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mourits, M. P., Koornneef, L., Wiersinga, W. M., Prummel, M. F., Berghout, A., & van der Gaag, R. (1989) · British Journal of Ophthalmology · doi:10.1136/bjo.73.8.639 · Cited by 721
Relation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy
Bartalena, L., Marcocci, C., Bogazzi, F., Manetti, L., Tanda, M. L., Dell'Unto, E., Bruno-Bossio, G., Nardi, M., Bartolomei, M. P., Lepri, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380201 · Cited by 715
Self-citationManagement of Graves’ Ophthalmopathy: Reality and Perspectives*
Bartalena, L., Pinchera, A., & Marcocci, C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0393 · Cited by 677
Self-citationPathogenesis of Graves' Ophthalmopathy
Epstein, F. H., Bahn, R. S., & Heufelder, A. E. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292007 · Cited by 605
Graves' Ophthalmopathy: Current Concepts Regarding Pathogenesis and Management*
BURCH, H. B., & WARTOFSKY, L. (1993) · Endocrine Reviews · doi:10.1210/edrv-14-6-747 · Cited by 598
Randomised double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy
Prummel, M. F., Berghout, A., Wiersinga, W. M., Mourits, M. P., Koornneef, L., & Blank, L. (1993) · The Lancet · doi:10.1016/0140-6736(93)92001-a · Cited by 332
Bartalena, L., Marcocci, C., Chiovato, L., Laddaga, M., Lepri, G., Andreani, D., Cavallacci, G., Baschieri, L., & Pinchera, A. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-56-6-1139 · Cited by 272
Self-citationMarcocci, C. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.4.818 · Cited by 170
Self-citationClassification of Eye Changes of Graves' Disease
(1992) · Thyroid · doi:10.1089/thy.1992.2.235 · Cited by 162
Marcocci, C., Bartalena, L., Bogazzi, F., Bruno-Bossio, G., Lepri, A., & Pinchera, A. (1991) · Journal of Endocrinological Investigation · doi:10.1007/bf03347943 · Cited by 153
Self-citationMarcocci, C., Bartalena, L., Panicucci, M., Marconcini, C., Cartei, F., Cavallacci, G., Laddaga, M., Campobasso, G., Baschieri, L., & Pinchera, A. (1987) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1987.tb00836.x · Cited by 119
Self-citationWEISSEL, M., & Hauff, W. (2000) · Thyroid · doi:10.1089/thy.2000.10.521 · Cited by 101
Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy.
Kendall-Taylor, P., Crombie, A. L., Stephenson, A. M., Hardwick, M., & Hall, K. (1988) · BMJ · doi:10.1136/bmj.297.6663.1574 · Cited by 94
Treating severe Graves' ophthalmopathy
Bartalena, L., Marcocci, C., & Pinchera, A. (1997) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(97)80738-0 · Cited by 90
Self-citationMethylprednisolone Pulse Therapy in Severe Dysthyroid Optic Neuropathy
Guy, J. R., Fagien, S., Donovan, J. P., & Rubin, M. L. (1989) · Ophthalmology · doi:10.1016/s0161-6420(89)32784-9 · Cited by 64
Colao, A., Lastoria, S., Ferone, D., Pivonello, R., Macchia, P. E., Vassallo, P., Bonavolontà, G., Muto, P., Lombardi, G., & Fenzi, G. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.11.3790 · Cited by 43
High-Dose Intravenous Steroid Pulse Therapy in Thyroid-Associated Ophthalmopathy.
Tagami, T., Tanaka, K., Sugawa, H., Nakamura, H., Miyoshi, Y., Mori, T., & Nakao, K. (1996) · Endocrine Journal · doi:10.1507/endocrj.43.689 · Cited by 38
Chang, T., Huang, K.-M., Hsiao, Y., Tzeng, S., & Kao, S. C. S. (1997) · Acta Ophthalmologica Scandinavica · doi:10.1111/j.1600-0420.1997.tb00779.x · Cited by 15
Cited by
Smith, T. J., & Hegedüs, L. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510030 · Cited by 1,257
Bartalena, L., Kahaly, G. J., Baldeschi, L., Dayan, C. M., Eckstein, A., Marcocci, C., Marinò, M., Vaidya, B., Wiersinga, W. M., _, _., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0479 · Cited by 1,054
Self-citationConsensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO
Bartalena, L., Baldeschi, L., Dickinson, A., Eckstein, A., Kendall-Taylor, P., Marcocci, C., Mourits, M., Perros, P., Boboridis, K., Boschi, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0666 · Cited by 795
Self-citationTeprotumumab for Thyroid-Associated Ophthalmopathy
Smith, T. J., Kahaly, G. J., Ezra, D. G., Fleming, J. C., Dailey, R. A., Tang, R. A., Harris, G. J., Antonelli, A., Salvi, M., Goldberg, R. A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614949 · Cited by 756
Pharmacokinetics and Pharmacodynamics of a Sustained-Release Dexamethasone Intravitreal Implant
Chang-Lin, J.-E., Attar, M., Acheampong, A. A., Robinson, M. R., Whitcup, S. M., Kuppermann, B. D., & Welty, D. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5285 · Cited by 590
Metadata
- Authors
- Marcocci, C.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2001-08-01
- Volume
- 86
- Issue
- 8
- Pages
- 3562-3567
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2169945487
- Cited by
- 309
- References
- 18
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.